Nexalin Technology, Inc. NXL

Nexalin Technology (NXL) signed an agreement to appoint Inovanexa Medical Technologies as its exclus

The 10-year exclusive agreement covers seven countries and includes an initial binding device order, a Brazilian clinical pilot and a framework for locally manufactured devices and recurring electrode royalties. Key Investor TakeawaysNexalin Technology (NASDAQ:NXL) signed a definitive exclusive South America distribution agreement with Inovanexa Medical Technologies covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela.

Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexalin Sync™ across seven countries and more than 300 million people, with a structured pricing framework and a mechanism for larger strategic transactions with government and private-sector customers Agreement establishes a 10-year commercial framework covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, anchored by an initial 100-device commercialization program and minimum re

Appointment as Senior Strategic Advisor marks the Company’s expansion from clinical development toward commercialization of its DIFS™ platform in the United States, Europe and South America DiTota spent over two decades in neuromodulation at Abbott and Medtronic, two of the largest companies in the field, including responsibility for Abbott’s North America commercial neuromodulation business, a division representing approximately $700 million in business Nexalin’s Gen-2 SYNC device is already ap

ORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (NASDAQ:ANIX) and Nexalin Technology Inc.

Further analysis of ADAS-Cog data from the Company’s randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer’s Disease and in Radiology — identifies specific improvements in cognitive domains associated with memory in Alzheimer’s patients One half of evaluable active-arm participants achieved a clinically meaningful improvement of four or more points on the ADAS-Cog, with domain-level gains in comprehension, memory and language function still evident three m

HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios. The reverse stock split will become effectiv

Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin’s recently completed Brazilian clinical study, received the Young Researcher Award at BRAIN 2026 – Congress on Brain, Behavior and Emotions, held in Porto Alegre, Brazil Award-winning research evaluated Nexalin’s DIFS™ 15 mA, 77.5 Hz platform for insomnia symptoms in patients with comorbid anxiety, with the primary reported finding being a significant, durable improvement in sleep quality Independent scientific recognition further

Accepted abstracts showcase Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life Data to be presented include 77.8% anxiety response rate at end of treatment, durable benefits maintained at 8-week follow-up and no serious adverse events, seizures or manic/hypomanic switches reported Presentations of clinical data further strengthen the scientific viability of Nexalin’s new proprietary non-invasive approach

The Australian market is currently experiencing a positive shift, with shares advancing on the news of a potential peace agreement between Iran and the U.S., which has traders optimistic about stability in global oil flows. In this environment, identifying undervalued stocks can be particularly rewarding as investors seek opportunities that are priced below their intrinsic value, such as Capricorn Metals and two other promising picks.

Study using Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up Results further validate Nexalin’s prior clinical data and support the Company’s differentiated, non-invasive approach to deep frequency-based neurostimulation No serious adverse events, seizures or manic/hypomanic switches were reported, reinforcing the favorable tolerability profile of Nexalin’s technolo

Nexalin Technology Inc. (NASDAQ:NXL) on Wednesday reported clinical trial results in Brazil. The trial showed improvements in anxiety, depression, insomnia, and quality-of-life measures, supporting its drug-free neurostimulation approach. Anxiety Response Reached 77.8% Nexalin said an 8-week clinical trial in Brazil showed a 77.8% anxiety response rate. The rate applied to adults with generalized anxiety disorder and comorbid insomnia at the end of treatment. The Institute of Psychiatry, Hospita

Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin’s proprietary position in non-invasive frequency-based deep-brain neurostimulation Patent covers transcranial alternating current dynamic frequency stimulation methods for anxiety, depression and insomnia — three large and underserved markets central to Nexalin’s HALO™ Clarity and NeuroCare™ strategies HOUSTON, TX, June 04, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, In

U.S. House Appropriations Committee report language directs VA to support additional research evaluating non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant traumatic brain injury Report language, championed through the Nexalin America division, builds on Nexalin’s ongoing UC San Diego / San Diego VA-related TBI clinical research program Marks second Congressional action this year referencing non-invasive deep brain neurostimulation as an emerging therapy

Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSDHOUSTON, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( (Nasdaq: NXL) (“Nexalin” or the “Company”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its acquisition of PONM, Inc. (“PONM”) from GreenLight Ventures, LLC (“GreenLight”). PONM is the digital he